Top

European Journal of Orthopaedic Surgery & Traumatology

Published in:

01-12-2020 | Endoprosthesis | Original Article

Silver-coated (PorAg^®) endoprosthesis can be protective against reinfection in the treatment of tumor prostheses infection

Authors: Andrea Sambri, Riccardo Zucchini, Claudio Giannini, Eleonora Zamparini, Pierluigi Viale, Davide Maria Donati, Massimiliano De Paolis

Published in: European Journal of Orthopaedic Surgery & Traumatology | Issue 8/2020

Abstract

Introduction

We aim to evaluate the use of silver (PorAg^®) coated compared to uncoated prosthesis in two-stage revision for prosthetic joint infection (PJI) of distal femur and proximal tibia megaprosthesis in oncological patients.

Materials and methods

In total, 68 patients were retrospectively evaluated. Median age was 30 years (range 14–83). In total, 29 patients were re-implanted with PorAg^® prosthesis and 39 with uncoated prosthesis (Megasystem C^®, Waldemar Link GmbH & Co. KG, Hamburg, Germany). All patients had PJI confirmed according to Musculoskeletal Infection Society (MSIS) criteria. In 10 cases, no microorganism was identified at the time of first-stage revision, but all had a sinus communicating with the prosthesis.

Successful eradication of the infection was defined by the absence of clinical/serologic evidence of infection at 6 months after the second stage or at latest follow-up. Infection was again defined according to the MSIS criteria.

Results

At 3-year follow-up, estimated reinfection rate in the silver group was slightly lower than in uncoated EPR (10.3% vs. 17.5%, p = 0.104). Among reinfected patients, only one out of three patients (33%) in the silver group required an amputation compared to 80% in the nonsilver group (p = 0.047).

Conclusions

Our results show the efficacy of PorAg^® coating in the two-stage revision of knee EPR. PorAg^®-coated EPR may have possible advantages over this traditional strategy, in particular when applied to patients with a higher risk of reinfection.

Jeon DG, Kawai A, Boland P, Healey JH (1999) Algorithm for the surgical treatment of malignant lesions of the proximal tibia. Clin Orthop Relat Res 358:15–26CrossRef

Flint MN, Griffin AM, Bell RS, Wunder JS, Ferguson PC (2007) Two-stage revision of infected uncemented lower extremity tumor endoprostheses. J Arthroplast 22(6):859–865CrossRef

Gosheger G, Gebert C, Ahrens H, Streitbuerger A, Winkelmann W, Hardes J (2006) Endoprosthetic reconstruction in 250 patients with sarcoma. Clin Orthop Relat Res 450:164–171CrossRef

Henderson ER, O’Connor MI, Ruggieri P, Windhager R, Funovics PT, Gibbons CL, Guo W, Hornicek FJ, Temple HT, Letson GD (2014) Classification of failure of limb salvage after reconstructive surgery for bone tumours: a modified system including biological and expandable reconstructions. Bone Joint J 96-B(11):1436–1440CrossRef

Jeys LM, Grimer RJ, Carter SR, Tillman RM (2005) Periprosthetic infection in patients treated for an orthopaedic oncological condition. J Bone Joint Surg Am 87(4):842–849CrossRef

Parry MC, Laitinen MK, Albergo JI, Gaston CL, Stevenson JD, Grimer RJ, Jeys LM (2018) Silver-coated (Agluna(R)) tumour prostheses can be a protective factor against infection in high risk failure patients. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 45:704–710

Sambri A, Bianchi G, Parry M, Frenos F, Campanacci D, Donati D, Jeys L (2018) Is arthrodesis a reliable salvage option following two-stage revision for suspected infection in proximal tibial replacements? A multi-institutional study. J Knee Surg 32:911–918PubMed

Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J (2012) Economic burden of periprosthetic joint infection in the United States. J Arthroplast. 27(8 Suppl):61–65CrossRef

Neut D, van Horn JR, van Kooten TG, van der Mei HC, Busscher HJ (2003) Detection of biomaterial-associated infections in orthopaedic joint implants. Clin Orthop Relat Res 413:261–268CrossRef

10.

Ercolano LB, Christensen T, McGough R, Weiss K (2013) Treatment solutions are unclear for perimegaprosthetic infections. Clin Orthop Relat Res 471(10):3204–3213CrossRef

11.

Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM, Rao N, Hanssen A, Wilson WR (2013) Infectious Diseases Society of A. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis Off Publ Infect Dis Soc Am 56(1):e1–e25CrossRef

12.

Del Pozo JL, Patel R (2009) Clinical practice. Infection associated with prosthetic joints. New Engl J Med 361(8):787–794CrossRef

13.

Parvizi J, Gehrke T (2014) International consensus group on periprosthetic joint I. Definition of periprosthetic joint infection. J Arthroplast 29(7):1331CrossRef

14.

Wafa H, Grimer RJ, Reddy K, Jeys L, Abudu A, Carter SR, Tillman RM (2015) Retrospective evaluation of the incidence of early periprosthetic infection with silver-treated endoprostheses in high-risk patients: case-control study. Bone Joint J 97-B(2):252–257CrossRef

15.

Brennan SA, Ni Fhoghlu C, Devitt BM, O’Mahony FJ, Brabazon D, Walsh A (2015) Silver nanoparticles and their orthopaedic applications. Bone Joint J 97-B(5):582–589CrossRef

16.

Hardes J, von Eiff C, Streitbuerger A, Balke M, Budny T, Henrichs MP, Hauschild G, Ahrens H (2010) Reduction of periprosthetic infection with silver-coated megaprostheses in patients with bone sarcoma. J Surg Oncol 101(5):389–395CrossRef

17.

Scoccianti G, Frenos F, Beltrami G, Campanacci DA, Capanna R (2016) Levels of silver ions in body fluids and clinical results in silver-coated megaprostheses after tumour, trauma or failed arthroplasty. Injury 47(Suppl 4):S11–S16CrossRef

18.

Zajonz D, Birke U, Ghanem M, Prietzel T, Josten C, Roth A, Fakler JKM (2017) Silver-coated modular Megaendoprostheses in salvage revision arthroplasty after periimplant infection with extensive bone loss—a pilot study of 34 patients. BMC Musculoskelet Disorders 18(1):383CrossRef

19.

Cao H, Liu X, Meng F, Chu PK (2011) Biological actions of silver nanoparticles embedded in titanium controlled by micro-galvanic effects. Biomaterials 32(3):693–705CrossRef

20.

Qin H, Cao H, Zhao Y, Zhu C, Cheng T, Wang Q, Peng X, Cheng M, Wang J, Jin G, Jiang Y, Zhang X, Liu X, Chu PK (2014) In vitro and in vivo anti-biofilm effects of silver nanoparticles immobilized on titanium. Biomaterials 35(33):9114–9125CrossRef

21.

Parvizi J, Gehrke T, Chen AF (2013) Proceedings of the international consensus on periprosthetic joint infection. Bone Joint J 95B(11):1450–1452CrossRef

22.

Parvizi J, Tan TL, Goswami K, Higuera C, Della Valle C, Chen AF, Shohat N (2018) The 2018 definition of periprosthetic hip and knee infection: an evidence-based and validated criteria. J Arthroplast 33(5):1309–1314CrossRef

23.

Sambri A, Cadossi M, Giannini S, Pignatti G, Marcacci M, Neri MP, Maso A, Storni E, Gamberini S, Naldi S (2018) Is treatment with dithiothreitol more effective than sonication for the diagnosis of prosthetic joint infection? Clin Orthop Relat Res^® 476(1):137–145CrossRef

24.

Sambri A, Maso A, Storni E, Megaloikonomos PD, Igoumenou VG, Errani C, Mavrogenis AF, Bianchi G (2018) Sonication improves the diagnosis of megaprosthetic infections. Orthopedics 15:1–5

25.

Sambri A, Pignatti G, Romagnoli M, Donati D, Marcacci M, Cadossi M (2017) Intraoperative diagnosis of Staphylococcus aureus and coagulase-negative Staphylococcus using Xpert MRSA/SA SSTI assay in prosthetic joint infection. New Microbiol 40(2):130–134PubMed

26.

Wang TY, Dormans JP, Chang B (2012) Soft-tissue optimization of limb salvage with knee endoprosthesis: the 10-year experience at the Children’s Hospital of Philadelphia. Ann Plast Surg 69(5):560–564CrossRef

27.

Grimer RJ, Belthur M, Chandrasekar C, Carter SR, Tillman RM (2002) Two-stage revision for infected endoprostheses used in tumor surgery. Clin Orthop Relat Res 395:193–203CrossRef

28.

Hussmann B, Johann I, Kauther MD, Landgraeber S, Jager M, Lendemans S (2013) Measurement of the silver ion concentration in wound fluids after implantation of silver-coated megaprostheses: correlation with the clinical outcome. BioMed Res Int 2013:763096CrossRef

29.

Glehr M, Leithner A, Friesenbichler J, Goessler W, Avian A, Andreou D, Maurer-Ertl W, Windhager R, Tunn PU (2013) Argyria following the use of silver-coated megaprostheses: no association between the development of local argyria and elevated silver levels. Bone Joint J 95-B(7):988–992CrossRef

30.

Hardes J, Henrichs MP, Hauschild G, Nottrott M, Guder W, Streitbuerger A (2017) Silver-coated megaprosthesis of the proximal tibia in patients with sarcoma. J Arthroplast 32(7):2208–2213CrossRef

31.

Hardes J, Ahrens H, Gebert C, Streitbuerger A, Buerger H, Erren M, Gunsel A, Wedemeyer C, Saxler G, Winkelmann W, Gosheger G (2007) Lack of toxicological side-effects in silver-coated megaprostheses in humans. Biomaterials 28(18):2869–2875CrossRef

32.

Medellin MR, Fujiwara T, Clark R, Stevenson JD, Parry M, Jeys L (2019) Mechanisms of failure and survival of total femoral endoprosthetic replacements. Bone Joint J 101-B(5):522–528CrossRef

33.

Piccioli A, Donati F, Giacomo GD, Ziranu A, Careri S, Spinelli MS, Giannini S, Giannicola G, Perisano C, Maccauro G (2016) Infective complications in tumour endoprostheses implanted after pathological fracture of the limbs. Injury 47(Suppl 4):S22–S28CrossRef

34.

Schmolders J, Koob S, Schepers P, Pennekamp PH, Gravius S, Wirtz DC, Placzek R, Strauss AC (2017) Lower limb reconstruction in tumor patients using modular silver-coated megaprostheses with regard to perimegaprosthetic joint infection: a case series, including 100 patients and review of the literature. Arch Orthop Trauma Surg 137(2):149–153CrossRef

35.

Wilding CP, Cooper GA, Freeman AK, Parry MC, Jeys L (2016) Can a silver-coated arthrodesis implant provide a viable alternative to above knee amputation in the unsalvageable, infected total knee arthroplasty? J Arthroplast. 31(11):2542–2547CrossRef

36.

Tan TL, Kheir MM, Tan DD, Parvizi J (2016) Polymicrobial periprosthetic joint infections: outcome of treatment and identification of risk factors. J Bone Joint Surg Am 98(24):2082–2088CrossRef

Title: Silver-coated (PorAg®) endoprosthesis can be protective against reinfection in the treatment of tumor prostheses infection
Authors: Andrea Sambri
Riccardo Zucchini
Claudio Giannini
Eleonora Zamparini
Pierluigi Viale
Davide Maria Donati
Massimiliano De Paolis
Publication date: 01-12-2020
Publisher: Springer Paris
Keywords: Endoprosthesis
Sarcoma
Published in: European Journal of Orthopaedic Surgery & Traumatology / Issue 8/2020
Print ISSN: 1633-8065
Electronic ISSN: 1432-1068
DOI: https://doi.org/10.1007/s00590-020-02705-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Silver-coated (PorAg^®) endoprosthesis can be protective against reinfection in the treatment of tumor prostheses infection

Abstract

Introduction

Materials and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2020

Intercalary bone graft of the tibia: case series and review of the literature

Mid-term outcomes of surgical management of complex, isolated radial head fractures: a multicentre collaboration

Achievement of optimal implant alignment using taper wedge stems with cup-first THA through the MIS antero-lateral approach

Does low body mass index constitute a risk of damage to the soft tissues during reaming for proximal femoral nailing? a cadaveric study

How do vertebroplasty and kyphoplasty affect the quality of life of patients with multiple myeloma spinal metastasis?

Outcome and complications of distal tibia fractures treated with intramedullary nails versus minimally invasive plate osteosynthesis and the role of fibula fixation